Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

Inclusion Criteria: * Age 18-75 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate bone marrow function (Absolute neutrophil count \>1000/mm\^3, Platelet count\>100000/mm\^3, Hemoglobin\>9gr/mm\^3) * Histologically- or cytologically- confirmed breast adenocarcinoma * No prior anthracycline-based chemotherapy as treatment of advanced breast cancer * No prior chemotherapy with ≥ 300mg/m2 doxorubicin or ≥ 540mg/m2 epirubicin as adjuvant setting * At least 4 weeks interval since prior anticancer treatment * Measurable disease as defined by the presence of at least one measurable lesion(except bone metastases, ascites or pleural effusions) * Life expectancy \> 3 months * Written informed consent Exclusion Criteria: * Pregnancy or nursing * Documented history of congestive heart failure (CHF), serious arrhythmia, or myocardial infarction (within 6 months) * Other invasive malignancy except nonmelanoma skin cancer or acute infection. * Radiation of measurable disease (except brain metastases) * Progressive brain metastases according to clinical or radiological criteria. * Brain metastases without prior radiation therapy